Eric Warren - Mar 1, 2022 Form 3 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Commercial Officer
Signature
/s/ Richard B. Bartram, by power of attorney
Stock symbol
ESPR
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
3
Date filed
3/9/2022, 03:53 PM
Next filing
Mar 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ESPR Common Stock 11.2K Mar 1, 2022 Direct F1
holding ESPR Common Stock 5.9K Mar 1, 2022 Direct F2
holding ESPR Common Stock 24K Mar 1, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the 2017 Inducement Equity Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of February 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date.
F2 These shares were acquired pursuant to a restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of July 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date.
F3 These shares were acquired pursuant to a performance-based restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each performance-based restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.